Navigation Links
Endo Pharmaceuticals Receives FDA Priority Review for New Formulation of Long-Acting Oxymorphone Designed to be Crush Resistant
Date:9/22/2010

CHADDS FORD, Pa., Sept. 22 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced that it recently received notification from the U.S. Food and Drug Administration (FDA) that Endo's new drug application (NDA) for its new oral formulation of long-acting oxymorphone, which is designed to be crush resistant, has been granted priority review status.  The FDA has set the action date under the Prescription Drug User Fee Act (PDUFA) for Jan. 7, 2011.

This new oxymorphone formulation is a semi-synthetic opioid analgesic intended for the treatment of moderate to severe chronic pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. It is a tablet formulation designed to resist crushing, breaking, powdering or pulverizing.  

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiary HealthTronics Inc., please visit www.endo.com.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Calif. , July 31, 2014 Lazarus ... of novel interventional devices to facilitate removal of blood ... Proceeds from the financing will support EU commercialization of ... filings for the Lazarus ReCover™ and Lazarus Cover™ in ... "This financing reflects investor confidence in the value of ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... New York results of AFF008, a ... disease. PD01A is the first therapy against the protein alpha-synuclein, ... The Michael J. Fox Foundation for Parkinson,s Research (MJFF) ... presented at the press conference on the impact a disease-modifying ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... WORTH, Texas, Aug. 24, 2011 The UNT System Board ... authorized in the 82nd Texas legislative session. As part of ... and UNT Dallas, the College of Pharmacy students will earn ... graduate portion of their classes on the UNT Health Science ...
... Technologies, Inc. ( www.heartsine.com ), a world leader in ... the samaritan ® PAD 300P Public Access ... a school serving children and young people with intellectual ... (AED) is now available for Camphill staff enabling ...
Cached Medicine Technology:UNT Regents Approve New College of Pharmacy 2HeartSine® Technologies Donates Lifesaving AED to Camphill Special School 2
(Date:8/1/2014)... US (PRWEB) August 01, 2014 Get ... in partnership with PitchBook presents the 3Q 2014 Private ... U.S private equity investment, exits and fundraising activity in ... insight to help plan for private equity endeavors for ... registration form to download it now. , About Merrill ...
(Date:7/31/2014)... California (PRWEB) July 31, 2014 Serious ... Dead Psychedelic Acid Test concert posters. Owsley Bear Stanley, ... logo for the Grateful Dead. According to Hawley, “The ... to promote acid test parties in San Francisco and ... were printed on three different colors of paper. They ...
(Date:7/31/2014)... Atlanta, GA (PRWEB) July 31, 2014 ... construction camera on its Ponce City Market project ... the historic Sears, Roebuck & Company building into best-in-class ... nears completion, OxBlue reviewed Jamestown’s experience with their construction ... needs. , Jamestown wanted a construction camera ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 United Theological ... 9 a.m. on Monday, September 15, with its 2014 ... Church, 3440 Shroyer Rd., Kettering, OH. Dr. Emma ... in the Emma Toussant Chair will speak on “Unexpected ... Dr. Justes’ teaching and research interests include pastoral care ...
(Date:7/31/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:United Theological Seminary to Open 144th Year 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... News) -- Successful treatment of major depression in mothers also ... a new study. Children of parents with major depression ... This study included 80 women with depression and their ... a U.S. National Institute of Mental Health trial designed to ...
... Scientists have shown that an experimental vaccine against the human ... contagious nonbacterial illnesses that cause diarrhea and vomiting can ... cause the animals any harm. Using a novel viral ... shown promise in other agents designed to fight such infections ...
... the first laparoscopic procedure was performed to remove a ... St. Louis, this breakthrough minimally invasive technique has become ... achievement is celebrated with a series of cutting-edge articles ... published by Mary Ann Liebert, Inc. ( www.liebertpub.com ). ...
... considered a safe procedure, although complications can occur. The ... reports perforation rates of 0.03%-0.8% for diagnostic procedures, and ... perforation are the result of either mechanical disruption of ... a diverticulum, or stretching of the bowel with loops ...
... successfully treated for depression are at higher risk of losing ... study in the March 15, 2011 issue of the journal ... third of those who experience a stroke develop depression, a ... of health and rehabilitation sciences and of medicine at Indiana ...
... Ben-Gurion University of the Negev (BGU) researchers have shown that ... may have Obstructive Sleep Apnea (OSA), which may be the ... study compared men between the ages of 55 and 75 ... BPE and reported nocturia at least once nightly. The comparison ...
Cached Medicine News:Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 2Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 3Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 4Health News:20th anniversary of first laparoscopic nephrectomy 2Health News:Managing post-stroke depression improves physical functioning 2Health News:Managing post-stroke depression improves physical functioning 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: